Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis.
The NF-kappa B/Rel family of transcription factors participates in the activation of a diverse range of genes involved in inflammation, immune response, lymphoid differentiation, growth control and development. The present review provides a brief overview of NF-kappa B/Rel activation and a detailed analysis of important biological and biochemical inhibitors of the NF-kappa B/Rel pathway. Given the pleiotropic role of NF-kappa B in controlling cytokines and other immunoregulatory genes, the inhibition of NF-kappa B activation by steroid hormones, antioxidants, protease inhibitors and other compounds may provide a pharmacological basis for interfering with pathological inflammatory conditions, cancer and AIDS.
Beauparlant
P
P
Terry Fox Molecular Oncology Group, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.
Hiscott
J
J
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology; D016207:Cytokines / Q000096:biosynthesis* / Q000187:drug effects; D015232:Dinoprostone / Q000494:pharmacology; D005544:Forecasting; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009154:Mutation; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D020572:Oncogene Proteins v-rel; D010766:Phosphorylation / Q000187:drug effects; D011480:Protease Inhibitors / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D015682:Retroviridae Proteins, Oncogenic / Q000187:drug effects* / Q000378:metabolism*; D016559:Tacrolimus / Q000494:pharmacology; D051841:Transcription Factor RelB; D014157:Transcription Factors
D000975:Antioxidants; D016207:Cytokines; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016328:NF-kappa B; D020572:Oncogene Proteins v-rel; D011480:Protease Inhibitors; D011518:Proto-Oncogene Proteins; C497593:RELB protein, human; D015682:Retroviridae Proteins, Oncogenic; D014157:Transcription Factors; D051841:Transcription Factor RelB; D009569:Nitric Oxide; D016572:Cyclosporine; D015232:Dinoprostone; D001241:Aspirin; D016559:Tacrolimus